Synergistic inactivation of AXL: a (cross)road to cure ovarian cancer? - Archive ouverte HAL Access content directly
Journal Articles EMBO Reports Year : 2018

Synergistic inactivation of AXL: a (cross)road to cure ovarian cancer?

(1)
1

Abstract

Comment on: The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer. [EMBO Rep. 2018] Inhibition of the receptor tyrosine kinase AXL, a key molecular driver of ovarian cancer, has recently been highlighted as promising therapeutic strategy. In this issue of EMBO Reports, Antony et al 1 have identified a novel mechanism of inhibition of AXL, wherein the GPI‐anchored tumour suppressor OPCML sequesters AXL into specialised plasma membrane domains where the phosphatase PTPRG is located, therefore facilitating AXL dephosphorylation. This [...]

Dates and versions

pasteur-02263624 , version 1 (05-08-2019)

Identifiers

Cite

Chiara Zurzolo. Synergistic inactivation of AXL: a (cross)road to cure ovarian cancer?. EMBO Reports, 2018, 19 (8), pp.e46492. ⟨10.15252/embr.201846492⟩. ⟨pasteur-02263624⟩
19 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More